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ABSTRACT
Myotonic Dystrophy type I (DM1) is caused by an
abnormal expansion of CTG triplets in the 30
UTR of the dystrophia myotonica protein kinase
(DMPK) gene, leading to the aggregation of the
mutant transcript in nuclear RNA foci. The
expanded mutant transcript promotes the seques-
tration of the MBNL1 splicing factor, resulting in the
misregulation of a subset of alternative splicing
events. In this study, we identify the DEAD-box
RNA helicase p68 (DDX5) in complexes assembled
onto in vitro-transcribed CUG repeats. We showed
that p68 colocalized with RNA foci in cells express-
ing the 30UTR of the DMPK gene containing
expanded CTG repeats. We found that p68
increased MBNL1 binding onto pathological
repeats and the stem–loop structure regulatory
element within the cardiac Troponin T (TNNT2)
pre-mRNA, splicing of which is misregulated in
DM1. Mutations in the helicase core of p68 pre-
vented both the stimulatory effect of the protein on
MBNL1 binding and the colocalization of p68 with
CUG repeats, suggesting that remodeling of RNA
secondary structure by p68 facilitates MBNL1
binding. We also found that the competence of p68
for regulating TNNT2 exon 5 inclusion depended on
the integrity of MBNL1 binding sites. We propose
that p68 acts as a modifier of MBNL1 activity on
splicing targets and pathogenic RNA.
INTRODUCTION
Myotonic dystrophy type 1 (DM1) is a dominant
autosomal neuromuscular disorder, characterized by
multisystemic defects affecting muscle, heart, brain and
endocrine systems (1). DM1 is one the most frequent
form of muscular dystrophy in adults that is caused by
an expansion of CTG triplets in the 30 untranslated region
of the dystrophia myotonica protein kinase (DMPK) gene
(2–4). The mutant allele is transcribed, correctly spliced
and polyadenylated but it is not translated into a
protein. Instead, expanded transcripts are retained in the
nucleus and accumulate as discrete RNA foci, located at
the boundary of nuclear speckles (5–7). However, nuclear/
cytoplasmic distribution of mutant DMPK remains con-
troversial as cytoplasmic aggregates have also been
detected (8). It is now well established that the expanded
CUG repeats are toxic for the cells and play a major role
in DM1 pathogenesis. Based on structural studies on short
CUG repeats, it has been proposed that expanded CUG
repeats fold into an imperfect hairpin structure that inter-
feres with the activities of RNA binding proteins and
alters their normal cellular function. The muscleblind-like
1 protein (MBNL1) was identiﬁed by its ability to bind to
CUG repeats (9). MBNL1 is a splicing factor that inter-
acts with RNA through its zinc-ﬁnger domains. Recently
it has been shown that MBNL1 binds to single-stranded
and structured RNA, which raises the question of how the
protein recognizes different RNA targets (10). In the DM1
context, MBNL1 colocalizes with nuclear foci of CUG
repeats and its sequestration by the expanded repeats
leads to a loss-of-function of the protein [review in refs
(11,12)]. Another RNA-binding protein involved in DM1
is CUGBP1. This factor plays an important role in several
post-transcriptional processing steps, including transla-
tion, RNA stability and alternative splicing. Instead of
being sequestered by the repeats, the steady-state level of
CUGBP1 is increased in DM1 tissues due to its
hyperphosphorylation by protein kinase C, leading to a
gain of activity of the protein (13). MBNL1 and CUGBP1
are antagonistic splicing factors that are involved in
the reprogramming of splicing events during fetal to
post-natal development in muscle (14). The sequestration
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are proposed to trigger the misregulation of alternative
splicing of a subset of muscle and brain-speciﬁc tran-
scripts, leading to the re-expression of fetal isoforms in
adult tissues. Several of these abnormal splicing events
correlate with clinical symptoms such as myotonia,
insulin resistance and heart conduction defects,
which are caused by the misregulation of the muscle-
chloride channel, insulin receptor (INSR) and cardiac
Troponin T (TNNT2) pre-mRNA, respectively (15–18).
In addition to MBNL1 and CUGBP1, other factors
such as transcription factors and hnRNP F/H have been
proposed to be involved in DM1 (19,20). However, their
function in the disease is unclear. Studies using the CUG
RNA ﬂy model have identiﬁed modiﬁers of CUG toxicity
phenotypes (21), suggesting that factors or signaling
pathway other than MBNL1 and CUGBP1 could be
involved in DM1 pathogenesis. Recently, the mislocali-
zation of the transcription factor SHARP in DM1 has
been associated with alteration of steady-state levels of
numerous mRNAs that are important for muscle develop-
ment (22). Moreover, a recent study has demonstrated
that the processing of the pre-miR1 is altered in DM1,
reinforcing the idea that other mechanisms are involved
in DM1 pathophysiology (23).
The aim of this work was to isolate new factors that
bind to CUG repeats. Using an afﬁnity chromatography
strategy with an RNA containing 95 pure CUG repeats,
we identiﬁed the RNA helicase p68 (DDX5). p68 is a
prototype of DEAD-box RNA helicase proteins. This
family is characterized by a conserved core, consisting of
nine conserved motifs including the DEAD signature,
which gives rise to the name to these proteins (24). p68
is involved in many aspects of RNA metabolism including
transcription, RNA processing, RNA export, translation
and mRNA degradation (25,26). Here, we show that p68
colocalizes with RNA foci in different cell types that
overexpressed expanded CUG repeats. In vitro experi-
ments suggest that p68 promotes a conformational
change of CUG repeats that favors MBNL1 binding or
stabilizes the complex through additional interactions. We
also found that p68 regulates alternative splicing of
TNNT2 exon 5 and we demonstrate that the competence
for regulation depends on MBNL1. From these results, we
propose that p68 acts as a modiﬁer of MBNL1 activity on
splicing targets and pathogenic RNAs.
MATERIALS AND METHODS
Plasmids and constructions
Plasmid CTG 95 was constructed by cloning polymerase
chain reaction (PCR) fragment containing CTG repeats in
plasmid pSP72 that was digested with PvuII. CTG repeats
were obtained by PCR using a sense oligonucleotide con-
taining 7 CTG repeats and an antisense oligonucleotide
containing 7 CAG repeats. PCR fragments containing
varying lengths of CTG repeats were puriﬁed on agarose
gel and cloned into the pSP72 plasmid. Several clones were
subjected to sequence analysis. According to the orienta-
tion of the repeats in the plasmid, different lengths of
CUG or CAG repeats were obtained. Plasmid CTG 95
contains 95 CTG repeats. Plasmid CAG 61 contains 61
CAG repeats. Plasmids containing 14 CTG repeats or 16
CAG repeats were chosen for gel retardation assays.
Plasmid-containing 62 CCTG repeats were obtained by
PCR using a sense oligonucleotide containing 6 CCTG
repeats and an antisense oligonucleotide containing 6
CAGG repeats. PCR fragments were cloned into the
pSP72 plasmid and proceed as for CTG and CAG
plasmids. Plasmids containing the 30UTR of DMPK
gene with 5 or 200 pure CTG repeats were described pre-
viously (27). Plasmid-expressing DMPK exons 11–15 con-
taining 960 interrupted CUG repeats in exon 15 were
described previously (28). The 30 UTR of DMPK gene
containing 960 interrupted CTG was also cloned into a
Tet-on inducible lentiviral construct as previously
described (29). Mutations in the helicase core domains II
and IV of human p68/DDX5 were made by reverse
PCR from pcDNA4 p68/Ha-Myc-His provided by
Dr D. Auboeuf. For mutation in domain II (p68 mt2),
sense and antisense oligonucleotides are 50-AGATAGA
ATGCTTGATATGGGC-30 and 50-GCTTCATTAAGG
ACAAGGTAGG-30, respectively. For mutation in
domain IV (p68 mt4), sense and antisense oligonucleotides
are 50-GCTGTGGAAACCAAAAGAAGA-30 and 50-AA
CAATGGTTTTATTCTCCTTCTC-30, respectively. The
wild-type and mutant 4G cardiac Troponin T (TNNT2)
minigenes were described previously (30). Mutant
TNNT2, CUG stem (CUGS) and GUF were described
previously (31). The TNNT2 RNA used for UV-cross-
linking experiments was generated by PCR from the
wild-type TNNT2 plasmid using sense and antisense
oligonucleotides (50-ACACATACGATTTAGGTGACA
CTATAGAACCCAGACTAACCTGT-30 and 50-CTGA
GGTTCAGGGAGTGG-30, respectively). Plasmid p68
for expression in Escherichia coli was generated by PCR
from pcDNA4 p68/Ha-Myc-His using a sense oligo-
nucleotide (50-ATCTAGGATCCATGTCGGGTTATTC
GA-30) and an antisense oligonucleotide (50-AGATCTC
GAGTTGGGAATATCCTGT-30). The PCR product
after digestion with NdeI and XhoI was cloned in a
variant of pet28 (gift from Dr H. Le Hir) that was
digested by NdeI and XhoI. This vector contained in the
N-terminal a CBP tag followed by a TEV protease and in
the C-terminal a His-tag (32). The deletion of a C-terminal
part of p68 giving rise to p68 Ct2 was made by reverse
PCR using a sense oligonucleotide (50-CTCGAGCACCA
CCACCACCACCACTGA-30) and an antisense oligo-
nucleotide (50-ATAATTTTCCCTGTCTCTAA-30) using
pet28/p68 as a template. p68Ct2 containing mutations
in the helicase core domains II and IV were made by
reverse PCR from wild-type p68 Ct2. Plasmid
pGEX-6P1-MBNL1/40kDa isoform was described previ-
ously (33).
Afﬁnity capture of protein complexes and
MALDI analysis
HeLa cell nuclear extracts were purchased from A. Miller
(Cilbiotech, B-7000 Mons, Belgium). Myoblast and
myotube nuclear extracts from C2C12 were prepared as
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repeats bound to streptavidin agarose were incubated
with 40% nuclear extracts under splicing conditions as
described (35). Proteins eluted from the beads were
separated by electrophoresis and detected by Coomassie
staining. Fourteen protein bands were excised from the gel
and identiﬁed using a nanoLC MS/MS-Orbitrap spec-
trometer (platform of proteomic of South-West Paris,
INRA).
Puriﬁcation of recombinant proteins
Recombinant protein GST-MBNL1 and GST-UAP56
(DDX39) were expressed in E. coli BL21 (DE3) and
puriﬁed using Glutathione Uniﬂow resin (BD biosciences
Clontech) according to standard procedure. GST-UAP56
was treated by thrombin to eliminate the GST tag accord-
ing to standard procedure. Recombinant protein p68
Ct2 and eIF4A3 were expressed in E. coli BL21 (DE3)
and successively puriﬁed on calmodulin resin (Stratagene)
and on nickel sepharose (GE-healthcare) as previously des-
cribed (32). Proteins were dialyzed against buffer D (36).
Western blot analysis and antibodies
Western blots were performed according to standard
procedure with the following antibodies: anti-MBNL1
monoclonal antibodies [MB1a(4A8), gift from Dr G.
Morris (7)], anti-p68 /DDX5 monoclonal antibodies (1/
200, SantaCruz, sc 81350), anti-p72/DDX17 polyclonal
antibodies (1/1000, Bethyl laboratories A300-509A),
anti-Myc monoclonal antibodies (1/500, sigma), anti-
Flag monoclonal antibodies (1/500), anti-Emerin (1/500,
SantaCruz, sc25284). The bands were detected with the
SuperSignal West Pico detection kit (Pierce) and
quantiﬁed with a Fuji LAS 3000.
UV-cross-linking, immunoprecipitation and gel
retardation experiments
RNAs for gel shift experiments and UV-cross-linking
experiments were transcribed using a cap analogue and
SP6 or T7 RNA polymerase in the presence of
[a-
32P]UTP or [a-
32P]CTP. Uniformly labeled RNA (10
fmol) were incubated for 15min at 30 C, in 10ml with
recombinant MBNL1 and p68 as indicated in the ﬁgures
under splicing conditions with 0.5mM ATP, 1mM MgCl2
and 20mM creatine-phosphate. Samples were UV
irradiated for 15min and treated with 0.3mg RNase
A and 10U of RNase T1 at 37 C for 30min.
Immunoprecipitation experiments were carried out as
described with anti-MBNL1 (clone 3A4, sc47740
SantaCruz) or p68 monoclonal antibodies immobilized
on A/G agarose (34). The cross-linked proteins were
resolved on a 10% sodium dodecyl sulfate (SDS) poly-
acrylamide gel and visualized by a PhosphorImager.
RNA mobility shift assays were performed as described
with recombinant MBNL1 and p68 Ct2 as indicated in
the ﬁgures (37). Recombinant proteins were diluted in
Dignam buffer D containing 0.5mg/ml bovine serum
albumin (BSA). The reaction was incubated for 15min
at 30 C and the protein complexes were resolved by elec-
trophoresis on a 4% non-denaturing polyacrylamide gel
(39/1), 0.5 Tris/Borate/EDTA buffer (TBE). RNA bands
were quantiﬁed using a PhosphorImager (Molecular
Dynamics).
Cell culture
Cos, HeLa and N1E115 cells were grown at 37 Ci n
Dulbecco’s-modiﬁed Eagle’s medium with 4500mg/l
D-glucose (DMEM) supplemented with 10% fetal bovine
serum and antibiotics. C2C12 cells were grown in the same
medium supplemented with 20% fetal bovine serum.
Human muscle cells were derived from primary human
satellite cells and immortalized as described (38). Cells
were grown in Ham’s F10 medium supplemented with
20% fetal bovine serum and antibiotics. Cultures of
human myoblasts were also infected with lentiviral
vector expressing the Tet-on inducible 960 CTG construct.
Transduction was carried out overnight in the presence of
polybrene (4mg/ml) as previously described (39). Cells
were grown in the same medium as above but with
50mg/ml Gentamicin (Invitrogen). For immunoﬂuores-
cence cells were seeded in 24-well vessel and grown to
 90% conﬂuence. Cells were co transfected with 0.4mg
of plasmids expressing the repeats and 0.4mg of plasmids
encoding proteins using lipofectamin 2000 (Invitrogen) ac-
cording to the manufacturer’s recommendations. For
plasmid DNA transfection, human muscle cells were
seeded in six-well vessel, and grown to  90% conﬂuence.
Cells were cotransfected with 0.5mg minigenes and protein
expression vectors with lipofectamine LTX plus reagent
(Invitrogen, ratio 3:1), according to the manufacturer’s
recommendations. Cells were harvested 24h later. RNA
and proteins were prepared from the same plates using
NucleoSpin RNA/protein kit (Macherey-Nagel) and
splicing patterns were analyzed by RT–PCR in the
presence of [
32P]dCTP as previously described (37). PCR
products were resolved on 6% denaturing polyacrylamide
gels and quantiﬁed using a PhosphorImager. siRNAs and
primers are listed in Supplementary Table S3. SiRNA
duplex was transfected at 50nM with lipofectamine
RNAiMAX (Invitrogen) in growth medium without anti-
biotics. Twenty-four hours later, the cells were
cotransfected with 50nM siRNA and 0.5mg of minigene
and p68 or MBNL1 expression plasmid using
lipofectamine 2000 (Invitrogen). The media was replaced
with growth medium lacking antibiotics 3h later. Cells
were harvested 24h after transfection of the minigene.
RNA and proteins were prepared as described above.
RNA–FISH combined with immunoﬂuorescence
FISH was done as described using (CAG)8-Cy3 DNA
oligonucleotide probe (40). Glass coverslips containing
plated cells were ﬁxed in 4% paraformaldehyde in PBS
(pH 7.4) for 20min and washed three times with PBS.
The coverslips were incubated for 5min in PBS/0.5%
Triton X-100 and washed three times with PBS before
prehybridization in 30% formamide, 2  SCC for
10min. The coverslips were hybridized for 2h at 37 Ci n
30% formamide, 2  SCC, 2mM vanadyl ribonucleoside,
10mg/ml BSA and 0.5mg (CAG)8-Cy3 DNA oligonucleo-
tide probe (Sigma). The coverslips were washed twice in
Nucleic Acids Research,2012, Vol.40, No. 7 31612  SCC/30% formamide at 42 C and twice in 1  SCC at
room temperature. Following FISH, the coverslips were
washed twice in PBS. The coverslips were incubated with
primary antibodies DDX5 (1/2000 dilution, Abcam
ab21696), c-myc (1/500 dilution, clone 9E10; Santa
Cruz), M2-FLAG (1/200 dilution, clone A2220, Sigma)
and polyclonal antibodies DDX17 (1/400 dilution,
Bethyl laboratories A300-509A) in PBS/0.1%BSA at
room temperature for 60min. The coverslips were
washed four times with PBS/0.1% Tween20 before incu-
bation with a goat anti-rabbit or rabbit anti-mouse sec-
ondary antibody conjugated with Alexa-Fluor 488 (1/1000
dilution; Molecular probes, Invitrogen) in PBS/0.1% BSA
for 60min. Then, the coverslips were incubated for 10min
in PBS/0.1% BSA/DAPI (1/10000 dilution) and rinsed
twice in PBS before mounting in Fluorescent Mouting
Medium (DAKO). Slides were examined using either a
simple ﬂuorescence microscope (Leica) or a Leica
DM4000 B confocal microscope, equipped with a Leica
100  HCX Plan Apo CS 1.40 objective, in 1-mm optical
sections.
RESULTS
p68/DDX5 and p72/DDX17 form aggregates
that colocalize with CUG repeats
In an attempt to ﬁnd novel factors involved in DM1
pathophysiology, protein complexes assembled onto
biotinylated CUG repeats were puriﬁed by afﬁnity chro-
matography on streptavidin-agarose beads. We veriﬁed
that MBNL1 from HeLa nuclear extracts became
cross-linked to a biotinylated RNA containing 95 pure
CUG repeats (Figure 1A). Therefore, streptavidin-agarose
beads coupled to the biotinylated (CUG)95 RNA was
used to capture protein complexes from HeLa or
myogenic nuclear extracts. After several washing steps,
proteins were eluted and separated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS–PAGE).
Numerous proteins were detected (Figure 1B). Some
are common to the three nuclear extracts tested while
others seemed to be speciﬁc to the cell type or to the dif-
ferentiation status of muscle cells (Figure 1B). Fourteen
bands were selected, from which about 100 proteins
were identiﬁed by mass-spectrometry (Figure 1B and
Supplementary Table S1). We focused on proteins that
presented interesting features regarding their properties
(double-stranded RNA proteins, splicing factors) or
because they are involved in myogenesis (Figure 1B). To
test the putative implication of the candidates in DM1, we
investigated the localization of the proteins by RNA–
FISH/immunoﬂuorescence experiments in Hela cells that
had been cotransfected with a plasmid encoding the
30UTR of the DMPK gene containing either 960 inter-
rupted CTG repeats (28) or non-expanded repeats
(5 CTG) as a control. Most of the candidates did not
colocalize with RNA foci as exempliﬁed by the RNA
helicase UAP56/DDX39 and the splicing factor CDC5L
(Supplementary Figure S1 and Supplementary Table S2).
In contrast, the RNA helicase p68 (DDX5) colocalized
with RNA foci (Figure 2). In the absence of expanded
repeats, myc-tagged p68 showed a diffuse localization in
the nucleoplasm. However in the presence of expanded
repeats, p68-myc formed aggregates that colocalized
with the foci as shown by FISH/immunoﬂuorescence
using anti-Myc monoclonal antibodies (Figure 2A). The
colocalization of exogenous p68 was not cell-line depend-
ent, because aggregates were observed in different cell
types such as myogenic (C2C12) and neuronal (NIE115)
cell lines (Supplementary Figure S2). We also showed that
p68 accumulates with CUG RNA foci in cells that had
been cotransfected with a 30UTR DMPK minigene con-
taining 200 pure CUG repeats (41) (Figure 2A). We next
tested whether endogenous p68 colocalizes with CUG
Figure 1. Afﬁnity capture of protein complexes from HeLa and myogenic nuclear extracts by an in vitro transcribed RNA containing 95 CUG
repeats. (A) MBNL1 is cross-linked to
32P-labeled CUG95 repeats. In vitro transcribed (CUG)95 or (CAG)61 RNAs labelled with [a-
32P]CTP were
incubated with 40% HeLa nuclear extracts. After UV cross-linking an aliquot was precipitated with anti-MBNL1 antibodies. The cross-linked
proteins were separated by SDS-PAGE. (B) Proteins from HeLa nuclear extracts, myoblast (Mb) and myotube (Mt) nuclear extracts from C2C12
were separated onto a 10% polyacrylamide denaturing gel and detected by Coomassie Brilliant Blue staining. Numbers 1 through 14 refer to bands
that have been cut out from the gel and identiﬁed by mass-spectrometry. A subset of proteins identiﬁed by mass spectrometry is indicated.
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antibodies conﬁrmed that endogenous p68 colocalized
with expanded CUG repeats (Figure 2B). p72 (DDX17)
is a paralog of p68 that is highly similar to p68 (42). p72
was also found in complexes associated with in vitro
transcribed 95 CUG repeats. We thus investigated
whether p72 colocalized with the 960 CUG repeats. The
results showed that p72 tagged with a ﬂag epitope and
endogenous p72 formed aggregates that colocalized with
RNA foci (Figure 2C and D). In conclusion, our results
suggest that the DEAD-box RNA helicases p68 and p72
are novel factors that localize in CUG RNA aggregates
that recruit MBNL1.
p68 is a modiﬁer of MBNL1 binding on CUG repeats
Structural analyses have shown that MBNL1 binds to
CUG repeats via its Watson-Crick interface, suggesting
that the long A-form stem of the CUG repeats must be
partially unfolded (43). One function ascribed to
DEAD-box RNA helicases is to separate strands of
short RNA duplexes to promote the remodeling of
RNA–protein complexes (25). As RNA chaperones,
these proteins facilitate the correct folding of
structured-RNA molecules (44). Thus, we hypothesized
that RNA helicase p68 and/or p72 could locally disrupt
the G–C pairs of the CUG helix allowing the recruitment
or the stabilization of MBNL1 to the repeats. To test
this hypothesis, recombinant protein MBNL1 was
cross-linked to in vitro transcribed
32P RNA containing
95 CUG repeats in the absence or presence of recombinant
p68 protein under splicing conditions. We focused on p68
because recombinant p72 was insoluble in our hands. To
increase the solubility of the recombinant p68 in E. coli,
100 amino-acids of p68 were deleted from the C-terminus,
keeping NLS and NES signals intact (45). This truncated
p68 protein (p68Ct2) was still able to colocalize with the
RNA foci of expanded CUG repeats and to regulate
splicing (see below) as did the full-length p68
(Supplementary Figure S3). As previously observed in
other studies (9), MBNL1 was cross-linked to CUG
repeats even in the absence of p68 (Figure 3A).
However, in the presence of increasing concentrations of
recombinant p68, the amount of MBNL1 cross-linked to
the repeats was signiﬁcantly increased (Figure 3A and sup-
plementary Figure S4). Immunoprecipation with mono-
clonal antibodies against MBNL1 conﬁrmed that the
cross-linked band was indeed MBNL1 (Figure 3B). As
already reported, p68 was not efﬁciently cross-linked to
RNA using UV-cross-linking (46). However, we con-
ﬁrmed the interaction of p68 with CUG repeats by gel
retardation assays (Supplementary Figure S5). It has
been shown that MBNL1 was recruited to RNA foci in
cells expressing CAG repeats (28). Thus, we tested
whether p68 had an effect on MBNL1 binding on these
repeats. Results shown in Figure 3C indicated that p68
was able to increase the binding of MBNL1 on CAG
repeats in a similar range to those obtained on CUG
repeats. Myotonic dystrophy type 2 (DM2) is the second
form of myotonic dystrophy (47). It has been shown that
expanded CCUG repeats in DM2 also form RNA foci
that recruit MBNL1 (48). Interestingly, the stimulating
effect of p68 was less efﬁcient on CCUG repeats than on
the other repeats (Figure 3C). This suggests that the effect
of p68 on MBNL1 binding might depend on particular
structural features embedded in the repeats. We next
tested whether the stimulating effect on MBNL1 binding
was speciﬁc to p68. UV-cross-linking experiments were
Figure 2. p68 and p72 colocalized with CUG RNA foci in HeLa cells.
(A) Cells were cotransfected with a plasmid encoding p68-myc and
plasmids expressing either 5, 200 or 960 CTG repeats. Expression of
p68-myc was detected by immunoﬂuorescence using monoclonal
anti-Myc antibodies, followed by rabbit anti-mouse A488 antibodies.
Foci were detected by RNA-FISH using Cy3-labeled (CAG)8 probes.
Nuclei were stained with DAPI. (B) Endogenous p68 colocalizes
with CUG repeats. p68/DDX5 was revealed with a DDX5 monoclo-
nal antibody. (C) Same experiment as in (A) except that cells were
cotransfected with a Flag-p72 expression vector. Expression of
Flag-p72 was detected by immunoﬂuorescence using anti-Flag
antibodies. (D) Endogenous p72 colocalizes with CUG repeats. P72/
DDX17 was revealed with DDX17 polyclonal antibodies.
Nucleic Acids Research,2012, Vol.40, No. 7 3163performed in the presence of UAP56/DDX39, one of the
candidates found in complexes assembled onto (CUG)95
repeats and another DEAD-box protein, eIF4A3. The
stimulation was markedly reduced in the presence of
either UAP56 or eIF4A3, suggesting that p68 exhibits spe-
ciﬁcity toward the repeats despite the fact that the cata-
lytic core of the DEAD-box helicase family is highly
conserved (Figure 3D). To further characterize the
requirement of p68 for MBNL1 binding, we tested
whether mutations that affected ATPase/helicase activity
and RNA binding altered the stimulatory effect of p68 on
MBNL1 binding. Mutations D248N of the DEAD-box
motif and mutation F346A in motif IV, which have been
shown to be important for these activities in other
DEAD-box proteins (24,49) reduced by 2-fold the ability
of p68 to stimulate MBNL1 binding (Figure 4A).
Consistent with this in vitro analysis, mutations in both
the DEAD motif and RNA binding motif IV abolish
colocalization of p68 to RNA foci (Figure 4B).
Altogether, these results suggest that p68 acts as a
speciﬁc factor to facilitate MBNL1 binding onto CUG
repeats. Previous experiments have proposed that
MBNL1 is a primary determinant of RNA foci formation
(50). To examine whether knockdown of both p68 and p72
by siRNA has an effect on RNA foci formation, human
muscle cells were transduced with a 960 CTG construct
under the control of a Tet-on inducible promoter. RNA
foci were detected as early as 1h following the addition of
doxycycline to the culture medium (Figure 5). In contrast,
the number of nuclei showing RNA foci was signiﬁcantly
reduced in induced cells treated by siRNA against p68 and
p72, particularly at the early time points (1, 3 and 6h)
following doxycycline addition. No difference could be
observed at 24h between induced-cells that were treated
or non-treated by siRNA against both p68 and p72
(Figure 5). Altogether, our results suggest that p68 and
p72 play a role in the formation of RNA foci by
facilitating the binding of MBNL1 and that the inter-
action of these proteins with RNA foci is transient.
p68 regulates alternative splicing of TNNT2 that is
misregulated in DM1
One of the characteristic features of DM1 is the
misregulation of alternative splicing of a subset of tran-
scripts that resulted in the re-expression of fetal isoforms
in adult tissues. It was shown that some of these events
are responsive to MBNL1. In this study, we have found
that p68 modiﬁes MBNL1 binding on CUG repeats.
Therefore, we wondered whether p68 played a role in
the regulation of alternative splicing events that are
regulated by MBNL1 and misregulated in DM1. To test
this hypothesis we ﬁrst inactivated both p68 and p72 by
siRNA interference using a siRNA that targeted both
proteins. Western blot analysis showed that about 95%
of p68 was depleted from the cells (Figure 6A). The level
of p72 depletion was also around 95% (Supplementary
Figure 3. p68 increases the binding of MBNL1 to 95 CUG repeats. (A) Plasmid (CUG)95 was in vitro transcribed in the presence of [a-
32P]UTP.
Labeled (CUG)95 RNA was incubated with a constant amount of recombinant MBNL1 protein (200ng) and increasing amounts of recombinant
p68Ct2 under splicing conditions with ATP. Proteins cross-linked to labeled RNA were separated on a 10% SDS–PAGE. Bottom image shows a
silver stain of a gel run in parallel. Note that p68 Ct2 migrates as two bands that are recognized by anti-p68 antibodies (data not shown). (B) The
cross-linked proteins shown in (A) were immunoprecipitated with anti-MBNL1 antibodies and separated by SDS-PAGE. (C) (CUG)95, (CAG)61
and (CCUG)62 RNAs were labeled with [a-
32P]CTP and used for UV-cross-linking experiments. (D) The increase of cross-linked MBNL1 to CUG
repeats is speciﬁc to p68. Labeled (CUG)95 was incubated with 200ng of recombinant MBNL1 protein and 25 or 75ng of recombinant p68Ct2,
UAP56 or eIF4A3 proteins. Quantiﬁcations result from three independent experiments, with error bars indicating standard deviation. *P<0.05,
**P<0.01, ***P<0.001.
3164 Nucleic Acids Research, 2012,Vol.40, No. 7Figure S6). The knockdown of both p68 and p72-activated
splicing of endogenous TNNT2 alternative exon 5 as
a MBNL1 knockdown did, but it had no effect on alter-
native splicing of INSR exon 11 or on either sarco/endo-
plasmic reticulum Ca2+-ATPase (ATP2A1) exon 22 or
MBNL1 exon 7 (Figure 6B). Thus, these results suggest
that p68 and/or p72 regulates a subset of alternative
splicing events. It has been found that p68 and p72
could display distinct functions. Notably, it has been
shown that p68 and p72 have different abilities to
activate splicing of the CD44 alternative exons (51). To
test whether the increase of TNNT2 exon 5 inclusion upon
inactivation of p68 and p72 was speciﬁc to one of these
two proteins, we performed individual p68 and p72
knockdown experiments. All of the siRNAs tested that
targeted different regions of p68 or p72 were able to
increase TNNT2 exon 5 inclusion (Supplementary
Figure S6). This suggests that both p68 and p72 are regu-
lators of splicing TNNT2 exon 5. Recently, it has been
proposed that MBNL1 binding sites identiﬁed in
TNNT2 are embedded in a stem–loop structure containing
pyrimidine-pyrimidine mismatches that is similar to the
CUG repeats, suggesting that MBNL1 recognizes these
structures through a common mechanism (31). Thus, we
hypothesized that RNA helicases p68 and p72 might fa-
cilitate MBNL1 binding in TNNT2 pre-mRNA as it does
for the CUG repeats. To test this proposal, we performed
UV-cross-linking experiments with an RNA encompass-
ing the regulatory stem–loop element. Figure 7A showed
that indeed p68 increased the binding of MBNL1 onto the
regulatory element. Then, we asked whether mutations
that reduce MBNL1 binding would impair regulation of
TNNT2 exon 5 by p68. To answer this question, we used
several TNNT2 minigenes (obtained from the groups of T.
Cooper and A. Berglund), in which several mutations had
been introduced to disrupt MBNL1 binding and/or the
stem–loop RNA structure (Figure 7B) (30,31). Human
myoblasts were cotransfected with wild-type and mutant
TNNT2 minigenes that include exon 4–6 and with vectors
overexpressing p68 or MBNL1. In agreement with siRNA
experiments, overexpression of p68 repressed exon 5 inclu-
sion as did MBNL1 (Figure 7B). As previously reported
by Ho et al. and Warf et al., the 4G minigene in which
mutations disrupted the RNA structure and MBNL1
binding did not respond to MBNL1 overexpression
(Figure 7B). Interestingly, the 4G mutant was no longer
able to respond to p68. In contrast, the CUGS mutant
that still responded to MBNL1 also remained responsive
to p68 regulation (Figure 7B). Finally, the GUF mutant
that resulted in complete inclusion of exon 5 and became
insensitive to MBNL1 regulation was also insensitive to
p68 regulation (Figure 7B). These results suggested that
the competence for regulating alternative splicing of
TNNT2 by p68 depended on the presence of MBNL1
binding sites and the ability of MBNL1 to regulate this
Figure 4. (A) Mutations in the helicase core domain of p68 modify its
ability to increase MBNL1 binding. UV-cross-linking experiments with
labeled (CUG)95 were performed with 200ng of recombinant MBNL1
and 25 or 75ng of wild-type recombinant p68Ct2 or p68Ct2
mutated in domain II (p68 mt2, mutation D248N), or in domain IV
(p68 mt4, mutation F346A). Quantiﬁcations result from three inde-
pendent experiments, with error bars indicating standard deviation.
*P<0.05, **P<0.01, ***P<0.001. (B) Mutations in the helicase
core domain of p68 strongly affect colocalization of the protein with
CUG repeats. RNA/FISH experiments were performed as described in
Figure 2 with wild-type p68-myc expressing vector or p68-myc express-
ing vectors mutated in domain II (DEAD) or IV.
Figure 5. P68 and p72 facilitate RNA foci formation. Human muscle
cells expressing 960-interrupted CTG repeats under the control of a
Tet-on inducible promoter was used to attend the early steps of
RNA foci formation. The number of nuclei containing foci was
determined at different times after doxycycline addition (1, 3, 6 and
24h) in non-treated or treated cells by siRNA to inhibit p68/p72.
SiRNA duplexes were transfected 48h before CUG repeats induction
by doxycycline. Quantiﬁcation results from three independent experi-
ments. Approximately 300 cells were counted for each condition, with
error bars indicating standard deviation *P<0.05, **P<0.01,
***P<0.001.
Nucleic Acids Research,2012, Vol.40, No. 7 3165transcript. Therefore, we can anticipate that the inactiva-
tion of MBNL1 would result in the inability of p68 to
regulate TNNT2 exon 5. To validate this hypothesis, we
ﬁrst cotransfected human myoblasts with the 30DMPK
UTR containing 5 or 960 CTG repeats and the TNNT2
minigene in the presence or absence of a vector coding for
p68 (Figure 8A). We used an expression vector encoding
PTB that is a repressor of exon 5 inclusion as a control
(52). As previously observed in other studies and consist-
ent with sequestration of MBNL1 by the repeats, express-
ing CUG repeats resulted in an increase of TNNT2 exon 5
inclusion (12) (Figure 8A). Interestingly, p68 was not able
to regulate inclusion of TNNT2 exon 5 when 960 CUG
repeats were expressed. In contrast, p68 was still able to
regulate TNNT2 exon 5 in control experiments where only
ﬁve CUG repeats were expressed. This ﬁnding was not due
to a general effect of the repeats on splicing, because re-
pression of exon 5 inclusions by PTB was the same regard-
less of the expressed CUG repeats length. We then tested
the ability of p68 to regulate TNNT2 exon 5 inclusions
after inactivation of MBNL1 by siRNA (Figure 8B). In
agreement with previous studies, knockdown of MBNL1
increased splicing of TNNT2 exon 5 (Figure 8B). As
already shown (Figure 8B), cotransfecting cells with a
plasmid coding p68 resulted in a 2-fold decrease of
Figure 7. RNA stem–loop mutations that abolish MBNL1 binding
impair the regulation by p68. (A) p68 stimulates binding of MBNL1
onto the stem–loop regulatory element of TNNT2. Labeled stem–loop
regulatory RNA was incubated with a constant amount of recombinant
MBNL1 protein (200ng) and increasing amounts of recombinant
p68Ct2. Proteins cross-linked to labeled RNA were separated on a
10% SDS–PAGE. The TNNT2 RNA used for cross-linking experi-
ments is indicated. (B) RT–PCR analysis of splicing of TNNT2
alternative exon 5 in wild-type and mutant minigenes. Schematic rep-
resentation of wild-type and mutant stem–loop structure within
TNNT2 intron 4 [adapted from ref. (31)] is shown. Human myoblast
cells were cotransfected with wild-type or mutant TNNT2 minigenes
and expression vector coding for p68 (lanes 2, 5, 8 and 11) or MBNL1
(lanes 3, 6, 9 and 12). The histogram shows the quantiﬁcation of exon 5
inclusion. Results are derived from at least three experiments, except
for lanes 4, 6, 7, 9, 10 and 12, which are derived from two experiments.
*P<0.05, **P<0.01, ***P<0.001. NS: non-speciﬁc.
Figure 6. p68 regulates splicing of TNNT2 alternative exon 5.
(A) Western blot analysis of human myoblasts treated with a control
luciferase siRNA, (siLuc), sip68/p72 or siMBNL1. About 15mg (lanes
1, 3 and 5) or 7.5mg (lanes 2, 4 and 6) of proteins were loaded per lane.
The blot was probed with antibodies against p68, MBNL1 and emerin
as a control. (B) RT–PCR analysis of endogenous transcripts in human
myoblast cells transfected with a control siRNA (siLuc), siRNA against
p68/p72 or siRNA against MBNL1. The histogram shows the quanti-
ﬁcation of exon inclusion. Results are derived from six independent
experiments for TNNT2 and four independent experiments for INSR,
MBNL1 and ATP2A1 with error bars indicating standard deviation.
*P<0.05, **P<0.01, ***P<0.001.
3166 Nucleic Acids Research, 2012,Vol.40, No. 7TNNT2 exon 5 splicing. In contrast, splicing of TNNT2
exon 5 became less sensitive to p68 when cells were
deprived of MBNL1. Consistent with these results,
splicing of TNNT2 exon 5 became unresponsive to the
knockdown of both p68 and p72 in DM1 myoblasts
(Supplementary Figure S7). Altogether, these results dem-
onstrate that p68 regulates the splicing of TNNT2 exon 5
alternative exon and suggest that p68-mediated regulation
depends on MBNL1 binding.
DISCUSSION
DEAD-box proteins are a well-characterized class of
RNA helicases that play essential roles in cellular
processes involving RNA (25,26). Their basic functions
are to remodel RNA and RNA–protein complexes. In
this study, we identiﬁed DEAD-box RNA helicases p68
and p72 in complexes that assembled onto pure CUG
repeats. We showed that these proteins colocalized
with RNA foci formed by the 30UTR of DMPK
mRNA-containing 200 or 960 CUG repeats. In particular,
we found that p68 increases the binding of MBNL1 onto
in vitro transcribed CUG repeats. Moreover, we showed
that TNNT2-mediated splicing regulation by p68 is de-
pendent on MBNL1 binding sites. On the basis of our
results we suggest that p68 acts as a modiﬁer of MBNL1
activity by facilitating the binding of MBNL1 onto the
repeats and splicing target.
Afﬁnity chromatography is a powerful method that
has been used to decode the composition of protein
complexes that assemble onto RNA. Using pure CUG
repeats as bait, about 100 proteins were identiﬁed by
mass-spectrometry. Many of them are hnRNP and are
involved in several aspect of RNA metabolism (Figure 1
and Supplementary Table 1). Surprisingly, MBNL1 was
not found in MS spectra. A similar observation was made
by Kim et al. (53), who also did not detect MBNL1 in
complexes puriﬁed using 46CUG repeats. However, in
accordance with Miller et al. (9), we showed that
MBNL1 is one of the major proteins from nuclear
extracts that becomes cross-linked to the 95 CUG
repeats (Figure 1A). In addition, MBNL1 was detected
in the elution fraction from the afﬁnity chromatography
by western blot analysis (data not shown). Thus, the
reason for the absence of MBNL1 from MS-spectra
is not completely understood. One possible explanation
is that, unfortunately, the band containing MBNL1
was not excised from the gel for identiﬁcation by
mass-spectrometry. Another possibility is that in our ex-
perimental conditions other proteins compete with
MBNL1 for binding to the repeats. Among the proteins
that we identiﬁed, only the DEAD-box proteins p68 and
p72 form aggregates that colocalize with expanded CUG
repeats. Interestingly, a study utilizing coexpression fre-
quency shows that MBNL1 is coexpressed with p68 and
p72, suggesting that these proteins could belong to the
same signaling pathway (54). Additionally, another
report shows that p68 is found in complexes associated
with MBNL1 in myoblasts (55). The colocalization of
p68 and p72 with RNA foci was observed with
overexpressed RNA containing interrupted 960 CUG
repeats or pure 200 CUG repeats and was independent
of the cell lines. We also found that endogenous p68 and
p72 colocalized with the repeats, as did exogenous
proteins, suggesting that p68 and p72 are indeed recruited
to RNA foci. However, in contrast to MBNL1 our results
also show that only a fraction of p68 and p72 aggregates
with RNA foci. p68 and p72 proteins are involved in
multiple biological pathways and play a crucial role
during development (25,26). It has been shown that the
Figure 8. Sequestration of MBNL1 by CUG repeats or MBNL1 knockdown by siRNA makes splicing of TNNT2 exon 5 non-responsive to p68.
(A) RT–PCR analysis of TNNT2 minigene in human myoblast cells cotransfected with the 30 UTR DMPK minigene containing 5 (lanes 1–3) or 960
(lanes 4 to 6) CTG repeats and a p68 expression vector (lanes 2 and 5) or as a control a PTB expression vector (lanes 3 and 6). The histogram shows
the quantiﬁcation of exon 5 inclusion. Results are from at least two experiments except lanes 3 and 6, for which a single experiment was performed.
(B) RT–PCR analysis of TNNT2 minigene in human myoblast cells transfected with a control siRNA (lanes 1 and 2) or siRNA against MBNL1
(lanes 3 and 4) and a p68 expression vector (lanes 2 and 4). The histogram shows the quantiﬁcation of exon 5 inclusion. Results are from four
experiments with error bars indicating standard deviation. *P<0.05, **P<0.01, ***P<0.001.
Nucleic Acids Research,2012, Vol.40, No. 7 3167disruption of either p68 or p72 genes in mice results in
a very severe phenotype that leads to early lethality (56).
In addition, the same study found that the processing of
several microRNAs involved in cell survival is affected in
p68 and p72 homozygous mice (56). Thus, according to
these ﬁndings, a sequestration mechanism of p68 and p72
that leads to a deﬁciency of protein function similar to
that of MBNL1 seems unlikely. In fact, no colocalization
of p68 with RNA foci could be observed in muscle tissues
from DM1 patients or mice expressing large CTG expan-
sions (data not shown). As recently reported, we never
observed recruitment of p68 in RNA foci of DM1
myoblasts (55). However, taking advantage of an indu-
cible system in which the expression of expanded CUG
repeats is under the control of an inducible promoter,
we were able to show that the knockdown of both p68
and p72 has an effect on RNA foci formation (Figure 5).
The effect on the number of newly formed foci was tran-
sient following doxycycline addition suggesting that p68
and p72 act at an early stage of RNA aggregation and
then are released from the RNA foci. Interestingly a
recent model has been proposed by Junghans to conciliate
some conﬂicting results of DM1 pathobiology. This model
poises the existence of insoluble and soluble RNA foci
with distinct binding properties (57). Thus, one possibility
would be that p68 and p72 intervene in the transition
between these two forms of RNA foci.
One general task of DEAD-box RNA helicase is to
modify RNA structure and/or RNA protein complexes
(25,26). A recent crystal analysis of two zinc-ﬁnger
domains of MBNL1 with a short CGCUGU RNA
shows that MBNL1 targets GC steps, indicating that
G–C base pairing within the helix has to be distorted
(43). On the basis of our results, we propose that the
recruitment of p68 to the CUG repeats would promote
structural changes of the RNA that would facilitate
and/or stabilize the binding of the splicing factor
MBNL1 to the repeats. Consistent with that proposal, mu-
tations in the helicase core domain of p68 strongly
decreased both the stimulation of p68 on MBNL1
binding and the colocalization of p68 with CUG repeats
(Figure 4). Although we focused on the role of p68, data in
other publications suggest that p68 and p72 can exist as
heterodimer in the cell (58). Indeed, our results show that
p68 and p72 have the same function, suggesting that at
least a fraction of p68 and p72 acts functionally as
heterodimers (Figure 2 and Supplementary Figure S6).
We also observed that the stimulatory effect operates on
CAG repeats and on the regulatory intronic sequence of
TNNT2 pre-mRNA (Figures 3C and 7A). Interestingly,
several biochemical and structural studies predicted that
pathogenic CUG repeats and TNNT2 RNA adopt
similar RNA secondary structure (31,59). For CAG
repeats, recent structural analysis also suggests that CAG
and CUG duplexes share structural similarities (60). Thus,
we can hypothesize that these common structural elements
compose the basis for p68 recognition and subsequently
for the increase of MBNL1 on the RNA. In contrast,
p68 only slightly increases the binding of MBNL1 onto
CCUG repeats. Interestingly, MBNL1 binds to CCUG
RNA with an afﬁnity 2-fold stronger than CUG RNA
(31). However, it has been shown that CCUG has a
decreased stability compared to CUG (31). Thus, it is
tempting to speculate that the requirement for p68 might
depend on the stability of the RNA structure. We can
suggest that the less an RNA is structured, the less p68
will be needed to distort the structure. Our results are con-
sistent with a recent study that shows that MBNL1 is able
to bind to both single-stranded and double-stranded
RNAs (10). The mechanism by which p68 favors the
binding of MBNL1 to the CUG repeats remains
unknown. Time course experiments show that there is a
huge increase of MBNL1 binding in the ﬁrst few minutes
following incubation with p68 (Supplementary Figure S4).
It is known that the DEAD-box RNA helicases as RNA
chaperones, modify the folding of RNA molecules. Thus,
we can speculate that p68 accelerates the transition from
misfolded RNA conformation to correct folding RNA
structure, suitable for MBNL1 binding. Several studies
point to the importance of U–U mismatches for MBNL1
binding (59,61). Thus, we propose that the mismatches
could provide an anchoring site for p68 from which local
strand separation could be initiated which would allow the
interaction of MBNL1 to the repeats. It also has been
shown that MBNL1 forms a ring-like structure with
CUG repeats. From this ﬁnding we can suggest that
in vivo p68 accelerates formation of this structure that is
proposed to be the basis for MBNL1 sequestration (59).
In this study, we provide evidence that the alternative
splicing of TNNT2, which is misregulated in DM1 is
regulated by p68. We also found that alternative splicing
of MBNL1 exon 7, ATP2A1 exon 22 or INSR exon 11,
which are regulated by MBNL1 and misregulated in
DM1, are not sensitive to p68 and/or p72, suggesting
that these proteins regulate speciﬁc classes of transcripts.
This ﬁnding raises an intriguing question. Why does alter-
native splicing of some transcripts regulated by MBNL1
require p68? The answer is not yet understood, but could
be related to the architecture of the MBNL1 binding sites.
Indeed, a recent study of Cass and coworkers suggests
that different modes of MBNL1 recognition must
operate for single-stranded and structured RNA targets
(10). In the case of TNNT2, MBNL1 binds to a short
stem–loop RNA structure, and we show that p68 increases
the binding of MBNL1 onto this RNA structure. In
contrast, at least for the INSR and MBNL1 transcripts
no potential RNA secondary structure has been identiﬁed
within the MBNL1 response element (62,63). Thus, we can
propose that p68 would be required only for splicing RNA
targets in which MBNL1 binding sites are embedded into
a stem–loop structure. The modiﬁcation of RNA stem–
loop structure is a common theme for regulating alterna-
tive splicing by p68. However, the mechanism by which
p68 mediates its effect is different according to the differ-
ent targets. In the case of alternative splicing of Tau exon
10 and IDX alternative exon of c-H-ras pre-mRNA, it has
been shown that p68 promotes the access of U1snRNP to
the 50 splice site (64) or block the binding of hnRNP H
(65), respectively. Our ﬁndings provide a new mode for
how p68 can regulate alternative splicing by increasing
the activity of a splicing factor. We also found that pre-
venting the binding of MBNL1 onto the RNA, either by
3168 Nucleic Acids Research, 2012,Vol.40, No. 7sequestration of the protein by expanded CUG repeats
or by mutations in the MBNL1 binding sites, made
TNNT2 exon 5 insensitive to p68 regulation. This
suggests that the repression of TNNT2 exon 5 by p68 is
dependent on MBNL1 binding to the regulatory element,
and it supports the idea that p68 would not act as a
splicing factor per se, but rather, would be a coregulator
or a coadaptator of MBNL1 binding. Thus, we favor a
model according to which p68 modiﬁes the stem–loop
RNA structure of TNNT2 as it does on the toxic CUG
repeats, which allows the stabilization of MBNL1.
In conclusion, our results have identiﬁed a modiﬁer of
MBNL1 activity. We suggest that through a common
mechanism, the DEAD-box RNA helicase p68 modiﬁes
the RNA secondary structures of splicing targets and
pathological RNAs to facilitate or stabilize MBNL1
binding that may contribute to the pathogenesis of DM1.
SUPPLEMENTARY DATA
Supplementary data is available at NAR Online:
Supplementary Tables 1–3, Supplementary Figures 1–7,
Supplementary Reference [66].
ACKNOWLEDGEMENTS
The authors are grateful to T. Cooper (Baylor University)
for DMPK CTG 960 plasmid, TNNT2 and mutant
TNNT2 4G minigenes; M. Mahadevan (University of
Virginia) for DMPK CTG 5 and CTG 200 plasmids;
A. Berglund (University of Oregon) for mutant TNNT2
CUGS and GUF plasmids; S. Kato (University of
Tokyo), F. Fuller-Pace (University of Dundee) and
D. Auboeuf (Centre Le ´ on Be ´ rard, Lyon) for p68 and
p72 plasmids; G. Morris (Centre for Inherited
Neuromuscular Disease; Robert Jones and Agnes Hunt
Orthopaedic Hospital) for the MBNL1 (MB1a) monoclo-
nal antibodies; H. Le Hir (Ecole Normale Supe ´ rieure,
Paris) for recombinant eIF4A3 protein; O. Cordin and
J. Banroques (Institut de Biologie Physico-chimique,
Paris) for recombinant UAP56 protein. N. Gourrier
and C. Branlant (Laboratoire AREMS, Nancy) for
GST-MBNL1 plasmid; N. Sergeant for N1E115 cells.
They acknowledge Kyle Tanner and Katriona Laurent-
Price for their constant interest and for carefully reading
the manuscript. They also thank all the members of the
French DM1 network for helpful discussions.
FUNDING
Centre National de la Recherche Scientiﬁque (CNRS);
Association Franc ¸ aise contre les Myopathies (AFM);
Paris-Sud University, the AFM and Fondation des
Treilles fellowships (to F.X.L.).
Conﬂict of interest statement. None declared.
REFERENCES
1. Harper,P.S. (2001) Myotonic Dystrophy. W. B. Saunders, London.
2. Brook,J.D., McCurrach,M.E., Harley,H.G., Buckler,A.J.,
Church,D., Aburatani,H., Hunter,K., Stanton,V.P., Thirion,J.P.,
Hudson,T. et al. (1992) Molecular basis of myotonic dystrophy:
expansion of a trinucleotide (CTG) repeat at the 30 end of a
transcript encoding a protein kinase family member. Cell, 68,
799–808.
3. Mahadevan,M., Tsilﬁdis,C., Sabourin,L., Shutler,G., Amemiya,C.,
Jansen,G., Neville,C., Narang,M., Barcelo,J., O’Hoy,K. et al.
(1992) Myotonic dystrophy mutation: an unstable CTG repeat in
the 3’ untranslated region of the gene. Science, 255, 1253–1255.
4. Fu,Y.H., Pizzuti,A., Fenwick,R.G. Jr, King,J., Rajnarayan,S.,
Dunne,P.W., Dubel,J., Nasser,G.A., Ashizawa,T., de Jong,P.
et al. (1992) An unstable triplet repeat in a gene related to
myotonic muscular dystrophy. Science, 255, 1256–1258.
5. Taneja,K.L., McCurrach,M., Schalling,M., Housman,D. and
Singer,R.H. (1995) Foci of trinucleotide repeat transcripts in
nuclei of myotonic dystrophy cells and tissues. J. Cell. Biol., 128,
995–1002.
6. Davis,B.M., McCurrach,M.E., Taneja,K.L., Singer,R.H. and
Housman,D.E. (1997) Expansion of a CUG trinucleotide repeat
in the 30 untranslated region of myotonic dystrophy protein
kinase transcripts results in nuclear retention of transcripts.
Proc. Natl Acad. Sci. USA, 94, 7388–7393.
7. Holt,I., Mittal,S., Furling,D., Butler-Browne,G.S., Brook,J.D. and
Morris,G.E. (2007) Defective mRNA in myotonic dystrophy
accumulates at the periphery of nuclear splicing speckles.
Genes Cells, 12, 1035–1048.
8. Schoser,B. and Timchenko,L. (2010) Myotonic dystrophies 1 and
2: complex diseases with complex mechanisms. Curr. Genomics,
11, 77–90.
9. Miller,J.W., Urbinati,C.R., Teng-Umnuay,P., Stenberg,M.G.,
Byrne,B.J., Thornton,C.A. and Swanson,M.S. (2000) Recruitment
of human muscleblind proteins to (CUG)(n) expansions
associated with myotonic dystrophy. EMBO J., 19, 4439–4448.
10. Cass,D.M., Hotchko,R., Barber,P., Jones,K., Gates,D.P. and
Berglund,J.A. (2011) The four Zn ﬁngers of MBNL1 provide a
ﬂexible platform for recognition of its RNA binding elements.
BMC Mol. Biol., 12, 20.
11. O’Rourke,J.R. and Swanson,M.S. (2009) Mechanisms of
RNA-mediated disease. J. Biol. Chem., 284, 7419–7423.
12. Ranum,L.P. and Cooper,T.A. (2006) RNA-mediated
neuromuscular disorders. Annu. Rev. Neurosci., 29, 259–277.
13. Kuyumcu-Martinez,N.M., Wang,G.S. and Cooper,T.A. (2007)
Increased steady-state levels of CUGBP1 in myotonic dystrophy
1 are due to PKC-mediated hyperphosphorylation. Mol. Cell, 28,
68–78.
14. Lin,X., Miller,J.W., Mankodi,A., Kanadia,R.N., Yuan,Y.,
Moxley,R.T., Swanson,M.S. and Thornton,C.A. (2006) Failure of
MBNL1-dependent post-natal splicing transitions in myotonic
dystrophy. Hum. Mol. Genet, 15, 2087–2097.
15. Charlet,B.N., Savkur,R.S., Singh,G., Philips,A.V., Grice,E.A. and
Cooper,T.A. (2002) Loss of the muscle-speciﬁc chloride channel
in type 1 myotonic dystrophy due to misregulated alternative
splicing. Mol. Cell, 10, 45–53.
16. Mankodi,A., Takahashi,M.P., Jiang,H., Beck,C.L., Bowers,W.J.,
Moxley,R.T., Cannon,S.C. and Thornton,C.A. (2002) Expanded
CUG repeats trigger aberrant splicing of ClC-1 chloride channel
pre-mRNA and hyperexcitability of skeletal muscle in myotonic
dystrophy. Mol. Cell, 10, 35–44.
17. Philips,A.V., Timchenko,L.T. and Cooper,T.A. (1998) Disruption
of splicing regulated by a CUG-binding protein in myotonic
dystrophy. Science, 280, 737–741.
18. Savkur,R.S., Philips,A.V. and Cooper,T.A. (2001) Aberrant
regulation of insulin receptor alternative splicing is associated
with insulin resistance in myotonic dystrophy. Nat. Genet, 29,
40–47.
19. Ebralidze,A., Wang,Y., Petkova,V., Ebralidse,K. and
Junghans,R.P. (2004) RNA leaching of transcription factors
disrupts transcription in myotonic dystrophy. Science, 303,
383–387.
20. Paul,S., Dansithong,W., Kim,D., Rossi,J., Webster,N.J., Comai,L.
and Reddy,S. (2006) Interaction of muscleblind, CUG-BP1 and
hnRNP H proteins in DM1-associated aberrant IR splicing.
EMBO J., 25, 4271–4283.
Nucleic Acids Research,2012, Vol.40, No. 7 316921. Garcia-Lopez,A., Monferrer,L., Garcia-Alcover,I., Vicente-
Crespo,M., Alvarez-Abril,M.C. and Artero,R.D. (2008) Genetic
and chemical modiﬁers of a CUG toxicity model in Drosophila.
PLoS One, 3, e1595.
22. Dansithong,W., Jog,S.P., Paul,S., Mohammadzadeh,R., Tring,S.,
Kwok,Y., Fry,R.C., Marjoram,P., Comai,L. and Reddy,S. (2011)
RNA steady-state defects in myotonic dystrophy are linked to
nuclear exclusion of SHARP. EMBO Rep., 12, 735–742.
23. Rau,F., Freyermuth,F., Fugier,C., Villemin,J.P., Fischer,M.C.,
Jost,B., Dembele,D., Gourdon,G., Nicole,A., Duboc,D. et al.
(2011) Misregulation of miR-1 processing is associated with heart
defects in myotonic dystrophy. Nat. Struct. Mol. Biol., 18,
840–850.
24. Cordin,O., Banroques,J., Tanner,N.K. and Linder,P. (2006)
The DEAD-box protein family of RNA helicases. Gene, 367,
17–37.
25. Fuller-Pace,F.V. (2006) DExD/H box RNA helicases:
multifunctional proteins with important roles in transcriptional
regulation. Nucleic Acids Res., 34, 4206–4215.
26. Janknecht,R. (2010) Multi-talented DEAD-box proteins and
potential tumor promoters: p68 RNA helicase (DDX5) and its
paralog, p72 RNA helicase (DDX17). Am. J. Transl. Res., 2,
223–234.
27. Amack,J.D., Paguio,A.P. and Mahadevan,M.S. (1999) Cis and
trans effects of the myotonic dystrophy (DM) mutation in a
cell culture model. Hum. Mol. Genet., 8, 1975–1984.
28. Ho,T.H., Savkur,R.S., Poulos,M.G., Mancini,M.A.,
Swanson,M.S. and Cooper,T.A. (2005) Colocalization of
muscleblind with RNA foci is separable from mis-regulation of
alternative splicing in myotonic dystrophy. J. Cell Sci., 118,
2923–2933.
29. Chaouch,S., Mouly,V., Goyenvalle,A., Vulin,A., Mamchaoui,K.,
Negroni,E., Di Santo,J., Butler-Browne,G., Torrente,Y., Garcia,L.
et al. (2009) Immortalized skin ﬁbroblasts expressing conditional
MyoD as a renewable and reliable source of converted human
muscle cells to assess therapeutic strategies for muscular
dystrophies: validation of an exon-skipping approach to restore
dystrophin in Duchenne muscular dystrophy cells. Hum. Gene
Ther., 20, 784–790.
30. Ho,T.H., Charlet,B.N., Poulos,M.G., Singh,G., Swanson,M.S. and
Cooper,T.A. (2004) Muscleblind proteins regulate alternative
splicing. EMBO J., 23, 3103–3112.
31. Warf,M.B. and Berglund,J.A. (2007) MBNL binds similar RNA
structures in the CUG repeats of myotonic dystrophy and its
pre-mRNA substrate cardiac troponin T. RNA, 13, 2238–2251.
32. Ballut,L., Marchadier,B., Baguet,A., Tomasetto,C., Seraphin,B.
and Le Hir,H. (2005) The exon junction core complex is locked
onto RNA by inhibition of eIF4AIII ATPase activity. Nat.
Struct. Mol. Biol., 12, 861–869.
33. Tran,H., Gourrier,N., Lemercier,C., Dhaenens,C.M., Vautrin,A.,
Fernandez-Gomez,F.J., Arandel,L., Carpentier,C., Obriot,H.,
Eddarkaoui,S. et al. (2011) Analysis of exonic-regions involved in
nuclear localization, splicing activity and dimerization of
muscleblind-like-1 isoforms. J. Biol. Chem., 286, 16435–16446.
34. Sauliere,J., Sureau,A., Expert-Bezancon,A. and Marie,J. (2006)
The polypyrimidine tract binding protein (PTB) represses splicing
of exon 6B from the beta-tropomyosin pre-mRNA by directly
interfering with the binding of the U2AF65 subunit. Mol. Cell
Biol., 26, 8755–8769.
35. Expert-Bezancon,A., Le Caer,J.P. and Marie,J. (2002)
Heterogeneous nuclear ribonucleoprotein (hnRNP) K is a
component of an intronic splicing enhancer complex that
activates the splicing of the alternative exon 6A from
chicken beta-tropomyosin pre-mRNA. J. Biol. Chem., 277,
16614–16623.
36. Dignam,J.D., Lebovitz,R.M. and Roeder,R.G. (1983) Accurate
transcription initiation by RNA polymerase II in a soluble extract
from isolated mammalian nuclei. Nucleic Acids Res., 11,
1475–1489.
37. Sureau,A., Sauliere,J., Expert-Bezancon,A. and Marie,J. (2011)
CELF and PTB proteins modulate the inclusion of the
beta-tropomyosin exon 6B during myogenic differentiation.
Exp. Cell Res., 317, 94–106.
38. Zhu,C.H., Mouly,V., Cooper,R.N., Mamchaoui,K., Bigot,A.,
Shay,J.W., Di Santo,J.P., Butler-Browne,G.S. and Wright,W.E.
(2007) Cellular senescence in human myoblasts is overcome by
human telomerase reverse transcriptase and cyclin-dependent
kinase 4: consequences in aging muscle and therapeutic strategies
for muscular dystrophies. Aging Cell, 6, 515–523.
39. Francois,V., Klein,A.F., Beley,C., Jollet,A., Lemercier,C.,
Garcia,L. and Furling,D. (2011) Selective silencing of mutated
mRNAs in DM1 by using modiﬁed hU7-snRNAs. Nat. Struct.
Mol. Biol., 18, 85–87.
40. Taneja,K.L. (1998) Localization of trinucleotide repeat sequences
in myotonic dystrophy cells using a single ﬂuorochrome-labeled
PNA probe. Biotechniques, 24, 472–476.
41. Amack,J.D. and Mahadevan,M.S. (2001) The myotonic dystrophy
expanded CUG repeat tract is necessary but not sufﬁcient to
disrupt C2C12 myoblast differentiation. Hum. Mol. Genet., 10,
1879–1887.
42. Lamm,G.M., Nicol,S.M., Fuller-Pace,F.V. and Lamond,A.I.
(1996) p72: a human nuclear DEAD box protein highly related to
p68. Nucleic Acids Res., 24, 3739–3747.
43. Teplova,M. and Patel,D.J. (2008) Structural insights into RNA
recognition by the alternative-splicing regulator muscleblind-like
MBNL1. Nat. Struct. Mol. Biol., 15, 1343–1351.
44. Woodson,S.A. (2010) Taming free energy landscapes with RNA
chaperones. RNA Biol., 7, 677–686.
45. Wang,H., Gao,X., Huang,Y., Yang,J. and Liu,Z.R. (2009) P68
RNA helicase is a nucleocytoplasmic shuttling protein. Cell Res.,
19, 1388–1400.
46. Liu,Z.R., Sargueil,B. and Smith,C.W. (1998) Detection of a novel
ATP-dependent cross-linked protein at the 5’ splice site-U1 small
nuclear RNA duplex by methylene blue-mediated photo-cross-
linking. Mol. Cell Biol., 18, 6910–6920.
47. Liquori,C.L., Ricker,K., Moseley,M.L., Jacobsen,J.F., Kress,W.,
Naylor,S.L., Day,J.W. and Ranum,L.P. (2001) Myotonic
dystrophy type 2 caused by a CCTG expansion in intron 1 of
ZNF9. Science, 293, 864–867.
48. Day,J.W. and Ranum,L.P. (2005) RNA pathogenesis of the
myotonic dystrophies. Neuromuscul Disord, 15, 5–16.
49. Banroques,J., Cordin,O., Doere,M., Linder,P. and Tanner,N.K.
(2008) A conserved phenylalanine of motif IV in superfamily 2
helicases is required for cooperative, ATP-dependent binding of
RNA substrates in DEAD-box proteins. Mol. Cell Biol., 28,
3359–3371.
50. Dansithong,W., Paul,S., Comai,L. and Reddy,S. (2005)
MBNL1 is the primary determinant of focus formation and
aberrant insulin receptor splicing in DM1. J. Biol. Chem., 280,
5773–5780.
51. Honig,A., Auboeuf,D., Parker,M.M., O’Malley,B.W. and
Berget,S.M. (2002) Regulation of alternative splicing by the
ATP-dependent DEAD-box RNA helicase p72. Mol. Cell Biol.,
22, 5698–5707.
52. Charlet,B.N., Logan,P., Singh,G. and Cooper,T.A. (2002)
Dynamic antagonism between ETR-3 and PTB regulates cell
type-speciﬁc alternative splicing. Mol. Cell, 9, 649–658.
53. Kim,D.H., Langlois,M.A., Lee,K.B., Riggs,A.D., Puymirat,J. and
Rossi,J.J. (2005) HnRNP H inhibits nuclear export of mRNA
containing expanded CUG repeats and a distal branch point
sequence. Nucleic Acids Res., 33, 3866–3874.
54. Wilson,B.J. and Giguere,V. (2007) Identiﬁcation of novel pathway
partners of p68 and p72 RNA helicases through Oncomine
meta-analysis. BMC Genomics, 8, 419.
55. Paul,S., Dansithong,W., Jog,S.P., Holt,I., Mittal,S., Brook,D.,
Morris,G.E., Comai,L. and Reddy,S. (2011) Expanded CUG
repeats dysregulate RNA splicing by altering the stoichiometry of
the muscleblind 1 complex. J. Biol. Chem., 286, 38427–38438.
56. Fukuda,T., Yamagata,K., Fujiyama,S., Matsumoto,T., Koshida,I.,
Yoshimura,K., Mihara,M., Naitou,M., Endoh,H., Nakamura,T.
et al. (2007) DEAD-box RNA helicase subunits of the Drosha
complex are required for processing of rRNA and a subset of
microRNAs. Nat. Cell Biol., 9, 604–611.
57. Junghans,R.P. (2009) Dystrophia myotonia: why focus on foci?
Eur. J. Hum. Genet., 17, 543–553.
58. Ogilvie,V.C., Wilson,B.J., Nicol,S.M., Morrice,N.A.,
Saunders,L.R., Barber,G.N. and Fuller-Pace,F.V. (2003)
3170 Nucleic Acids Research, 2012,Vol.40, No. 7The highly related DEAD box RNA helicases p68 and p72 exist
as heterodimers in cells. Nucleic Acids Res., 31, 1470–1480.
59. Yuan,Y., Compton,S.A., Sobczak,K., Stenberg,M.G.,
Thornton,C.A., Grifﬁth,J.D. and Swanson,M.S. (2007)
Muscleblind-like 1 interacts with RNA hairpins in splicing target
and pathogenic RNAs. Nucleic Acids Res., 35, 5474–5486.
60. Kiliszek,A., Kierzek,R., Krzyzosiak,W.J. and Rypniewski,W.
(2010) Atomic resolution structure of CAG RNA repeats:
structural insights and implications for the trinucleotide
repeat expansion diseases. Nucleic Acids Res., 38,
8370–8376.
61. Warf,M.B., Diegel,J.V., von Hippel,P.H. and Berglund,J.A. (2009)
The protein factors MBNL1 and U2AF65 bind alternative RNA
structures to regulate splicing. Proc. Natl Acad. Sci. USA, 106,
9203–9208.
62. Grammatikakis,I., Goo,Y.H., Echeverria,G.V. and Cooper,T.A.
(2011) Identiﬁcation of MBNL1 and MBNL3 domains required
for splicing activation and repression. Nucleic Acids Res., 39,
2769–2780.
63. Gates,D.P., Coonrod,L.A. and Berglund,J.A. (2011)
Auto-regulated splicing of the muscleblind-like 1 (MBNL1)
pre-mRNA. J. Biol. Chem., 286, 34224–34233.
64. Kar,A., Fushimi,K., Zhou,X., Ray,P., Shi,C., Chen,X., Liu,Z.,
Chen,S. and Wu,J.Y. (2011) RNA helicase p68 (DDX5) regulates
tau exon 10 splicing by modulating a stem-loop structure at the
50 splice site. Mol. Cell Biol., 31, 1812–1821.
65. Camats,M., Guil,S., Kokolo,M. and Bach-Elias,M. (2008)
P68 RNA helicase (DDX5) alters activity of cis- and trans-acting
factors of the alternative splicing of H-Ras. PLoS One, 3, e2926.
66. Uhlmann-Schifﬂer,H., Rossler,O.G. and Stahl,H. (2002)
The mRNA of DEAD box protein p72 is alternatively translated
into an 82-kDa RNA helicase. J. Biol. Chem., 277, 1066–1075.
Nucleic Acids Research,2012, Vol.40, No. 7 3171